UK’s NICE rejects Pfizer’s bosutinib cancer drug
NICE chief executive Sir Andrew Dillon said there is evidence to suggest that bosutinib was considered clinically effective for the treatment of CML. However, the manufacturer had provided
Summit Therapeutics’ partner Akeso has secured China’s National Medical Products Administration (NMPA) authorisation for the use of ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (NSCLC) patients.
The Swiss agency for therapeutic products, Swissmedic, cleared tofacitinib 5mg and 10mg twice-daily (BID) as monotherapy or combination therapy along with a disease modifying non-biologic antirheumatic agent (DMARD)
The Department of Industrial Policy & Promotion (DIPP), and the Department of Pharmaceuticals, including healthcare experts from the public health foundation of India, will participate in the discussion,